Table 4.
Treatment Characteristics Stratified by Tyrosine Kinase Inhibitor (TKI) Continuation
| TKI Discontinuation | TKI Continuation | ||||
|---|---|---|---|---|---|
| Number | % | Number | % | ||
| Patient who received chemotherapy | |||||
| Platinum alone* | 0 | 0 | 1 | 2.70% | |
| Platinum-based regimen (doublets) | 12 | 57.14% | 15 | 40.54% | |
| Other single-drug** | 3 | 14.29% | 10 | 27.03% | |
| Patient who received radiotherapy | |||||
| SBRT | 0 | 0 | 2 | 5.40% | |
| CRT | 1 | 4.70% | 8 | 21.62% | |
*Carboplatin, cisplatin, or nedaplatin.
**Docetaxel, paclitaxel, pemetrexed, gemcitabine, or vinorelbine.
SBRT: Stereotactic Body Radiation Therapy CRT: Conventional Radiation Therapy